Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Oncology therapeutics R&D by Year
Oncology therapeutics R&D ($M) ($M)
Moderna Oncology therapeutics R&D: $201M in FY2025, up 30.5% from a year earlier.
Latest, FY2025
201
Period ended Dec 31, 2025
Change on a year earlier
+30.5%
154 in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below
Where the FY2025 figure comes from
“Oncology | 201 | 154 | 62”
Source: FY2025 10-K ↗
Reported in Form 10-K Item 7 (MD&A R&D Program Breakdown).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Oncology therapeutics R&D ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 201 | +30.5% | FY2025 10-K ↗ |
| FY2024 | Dec 31, 2024 | 154 | +148.4% | FY2025 10-K ↗ |
| FY2023 | Dec 31, 2023 | 62 | +121.4% | FY2025 10-K ↗ |
| FY2022 | Dec 31, 2022 | 28 | – | FY2024 10-K ↗ |
Cite this data
StockData. (2026). Moderna Oncology therapeutics R&D ($M), annual FY2022–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/rd-oncology
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.